Reviews
Under 10% of Pancreatic Adenocarcinoma Recommendations Rest on High-Level Evidence, Review Notes
Pellat et alBMC medicine

The current research ecosystem for gastrointestinal (GI) cancers—including anal, colorectal, esogastric, pancreatic, hepatocellular, and biliary tract cancers—relies heavily on randomized controlled trials (RCTs), which involve high costs and limited transportability. Evidence gaps persist across the field: fewer than 10% of therapeutic recommendations for pancreatic adenocarcinoma are based on high-level evidence, a proportion that has not improved between 2011 and 2022. Furthermore, substantial research waste undermines interventional research in GI oncology, as 30% to 37% of completed GI cancer trials lack publicly available results and only 59% of gastric cancer trials are published as full-text articles, negatively impacting evidence synthesis and clinical guideline recommendations.
While interventional research remains the only method to evaluate the efficacy of a new drug, observational studies and real-world evidence (RWE)—derived from health records, cohorts, registries, and administrative databases—may offer complementary insights for questions that cannot be evaluated by RCTs. Specifically, RWE can evaluate treatments in elderly or comorbid patients who are routinely excluded from trials, inform clinical decisions for rare tumors such as digestive neuroendocrine neoplasms, and assess the real-world effectiveness of therapies including targeted agents and immunotherapy. Although RWE reliability was historically criticized for biases and data quality issues, methodological advances such as target trial emulation and data standardization have enhanced its validity, and agencies such as the Food and Drug Administration and the European Medicines Agency increasingly use RWE to support regulatory decisions. The authors conclude that better integration of high-quality interventional and observational approaches is essential, and guidance on selecting study designs based on the clinical question could reduce research waste, accelerate evidence generation, and help identify more effective personalized treatments for GI cancer patients.
Key Takeaways
- Fewer than 10% of therapeutic recommendations for pancreatic adenocarcinoma are based on high-level evidence, a proportion that did not improve between 2011 and 2022.
- Between 30% and 37% of completed gastrointestinal cancer trials lack publicly available results, and only 59% of gastric cancer trials are published as full-text articles.
Read the original sourceBMC medicine
